Your shopping cart is currently empty

Bimosiamose has anti-inflammatory effects[1]. Bimosiamose (TBC-1269) is a nonoligosaccharide pan-selectin antagonist with IC50s of 88 μM, 20 μM, and 86 μM for E-selectin, L-selectin, and P-selectin respectively.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $83 | 35 days | 35 days | |
| 5 mg | Inquiry | 35 days | 35 days |
| Description | Bimosiamose has anti-inflammatory effects[1]. Bimosiamose (TBC-1269) is a nonoligosaccharide pan-selectin antagonist with IC50s of 88 μM, 20 μM, and 86 μM for E-selectin, L-selectin, and P-selectin respectively. |
| Targets&IC50 | P-selectin:20 μM, Eselectin:88 μM, L-selectin:86 μM |
| In vitro | Bimosiamose (TBC-1269) effectively inhibits neutrophil recruitment to inflammation sites by obstructing the initial rolling phase of recruitment, without exhibiting cytotoxic effects on neutrophils. |
| In vivo | Bimosiamose (TBC-1269; 25 mg/kg; intravenous injection; Sprague-Dawley rats) treatment significantly increases survival, ameliorates neutrophil migration by 81%, and improves histologic damage scores[1]. The best overall survival rate of 70% is observed when administered 15 minutes before reperfusion, with a marked decrease in liver enzyme levels at 6 hours after reperfusion. |
| Synonyms | TBC-1269 |
| Molecular Weight | 862.91 |
| Formula | C46H54O16 |
| Cas No. | 187269-40-5 |
| Smiles | OC[C@H]1O[C@H](Oc2ccc(CCCCCCc3ccc(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)c(c3)-c3cccc(CC(O)=O)c3)cc2-c2cccc(CC(O)=O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |
| Relative Density. | 1.417 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | 0.1 M NaOH: 25 mg/mL (28.97 mM), when pH is adjusted to 10 with NaOH. Sonication is recommended. DMSO: 125 mg/mL (144.86 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (3.82 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
0.1 M NaOH/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.